Our immune system is the strongest line of defense against many diseases, including cancer. Cancer has some clever ways to evade detection and weaken immune cells. In recent months, Japanese researchers have discovered that a cancer patient T cells extracts, genetically engineered to target specific cancer cells, and put back into the body to hunt the cancer. CAR T-cell immunotherapy had done the experiment. This time, another team used a similar treatment, adding a new dimension to the fight against cancer with CAR T-cell immunotherapy.

A group of researchers from the University of Washington booster protein found that supplementation could significantly improve the outcome of cancer immunotherapy. Experiments in mice showed that the protein 10,000 times Lake immune cell revealed that all mice survived the entire experiment.

The treatment method was developed by changing the structure of the protein.

In the new study, scientists examined ways to fight cancer by increasing the number of T cells. Reportedly all-natural to boost T cell production in the body’s disease state interleukin-7 Using a protein called (IL-7) the researchers changed the structure of the natural protein, which normally doesn’t live very long in the body, allowing it to stay in the body for weeks.

The team injected this long-lived IL-7 into mice on several days. In the test, some mice received no immunotherapy, while others received CAR T-cell therapy without the IL-7 protein. When tumor-bearing and immunodeficient mice were injected with a long-acting IL-7 protein after CAR T cell therapy, CAR T cells were observed to increase more than ten thousand-fold in these mice compared to mice not receiving IL-7. It has also been observed that these CAR T cells fight against the harmful tumor for a longer period of time.

Human trials may begin soon

Thanks to this improved treatment, the survival time of the test mice was even longer. Tumors in the body of any mouse that received IL-7 protein with CAR T cell therapy on the 35th day undetectable shrunk† In addition, each of the mice lasted 175 days. during the experiment has been able to survive. In contrast, mice with immunotherapy treatment alone 30 days on average He appeared to have survived.

There may be instances where experiments in mice do not show the same effect in humans, but according to expert statements, clinical trials of CAR T cell therapy enhanced with IL-7 protein are expected to begin soon in patients with some type of lymphoma.